Background: Late-acquired incomplete stent apposition (ISA) has been reported in brachytherapy and bare-metal stents (BMS) and recently in drug-eluting stents. Previously, we reported that abciximab-coated stent produced a significant inhibition of neointimal hyperplasia and showed potential therapeutic benefit in the prevention of stent restenosis. Objectives: We sought to investigate the incidence and extent of ISA after abciximab-coated stent implantation in 69 patients (69 native lesions) and BMS implantation in 69 patients (69 native lesions) in whom intravascular ultrasound (IVUS) was performed at index and 6-month follow-up. Results: Late-acquired ISA at 6-month follow-up was observed in 7 patients and there was no difference in the incidence of ISA between both groups (abciximab-coated stent: n=3 [4.3%] vs BMS: n=4 [5.8%], P=0.698). Late-acquired ISA was the result of an increase in external elastic membrane area from post-stenting to follow-up (abciximab-coated stent: 14.8짹3.1 to17.5짹3.7 mm2 vs BMS: 14.7짹3.1 to17.7짹4.0 mm2, P=0.564) without change in plaque behind the stent. There was a tendency that ISA length was shorter and ISA volume was smaller in abciximab-coated stent group than those in BMS group, however, these were not statistically significant. There were no cardiac death, myocardial infarction, target lesion revascularization, and late stent thrombosis in patients with persistent ISA and late-acquired ISA after abciximab-coated stent implantation over a period of 12 months. Conclusion: The incidence of late ISA after abciximab-coated stent implantation was very low as observed in 4.3% of patients and there were no negative clinical events associated with late ISA at 12-month clinical follow-up.